The Use of Biologics for Thyroid Eye Disease.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 607, doi. 10.1007/s40259-025-00726-0
- By:
- Publication type:
- Article
Works matching IS 11738804 AND DT 2025 AND VI 39 AND IP 4
Results: 11
1
2
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 573, doi. 10.1007/s40259-025-00729-x
- By:
- Publication type:
- Article
3
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 555, doi. 10.1007/s40259-025-00728-y
- By:
- Publication type:
- Article
4
Beyond Cost: Observations on Clinical and Patient Benefits of Biosimilars in Real-World Settings.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 537, doi. 10.1007/s40259-025-00727-z
- By:
- Publication type:
- Article
5
Author's Reply to Gonçalves: "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".
- Published in:
- 2025
- By:
- Publication type:
- Letter to the Editor
6
Comment on "Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review".
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 669, doi. 10.1007/s40259-025-00724-2
- By:
- Publication type:
- Article
7
Progress and Challenges in the Treatment of Fabry Disease.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 517, doi. 10.1007/s40259-025-00723-3
- By:
- Publication type:
- Article
8
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 645, doi. 10.1007/s40259-025-00722-4
- By:
- Publication type:
- Article
9
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 635, doi. 10.1007/s40259-025-00721-5
- By:
- Publication type:
- Article
10
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 591, doi. 10.1007/s40259-025-00719-z
- By:
- Publication type:
- Article
11
Interrogation of Structure–Activity Relationships in Charge Variants of Therapeutic IgG2s Enabled by Free-Flow Isoelectric Focusing Fractionation.
- Published in:
- BioDrugs, 2025, v. 39, n. 4, p. 621, doi. 10.1007/s40259-025-00718-0
- By:
- Publication type:
- Article